LaurenCSeebergerMD

PubMed

• Short-Term Cannabidiol with Δ-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
  Ying Liu, Jacquelyn Bainbridge, Stefan Sillau, Sarah Rajkovic, Michelle Adkins, Christopher H Domen, John A Thompson, Tristan Seawalt, Jost Klawitter, Cristina Sempio,...> ;Movement Disorders. 2024 Mar 15
• Assessing the state of care for Huntington disease in the United States: Results from a survey of practices treating Huntington disease patients.
  Lauren Seeberger, Jody Corey-Bloom, Michael O'Brien, Diana Slowiejko, Danielle Schlang, Marika S Booth, Beth Ann Griffin, Peggy G Chen> ;Clinical Parkinsonism & Related Disorders. 2022 Jan 1
• 8 citations
  Scoliosis in Friedreich's ataxia: longitudinal characterization in a large heterogeneous cohort.
  Christian Rummey, John M. Flynn, Louise A. Corben, Martin B. Delatycki, George Wilmot, S. H. Subramony, Khalaf Bushara, Antoine Duquette, Christopher M. Gomez, J. Chad...> ;Annals of Clinical and Translational Neurology. 2021 May 5
• 72 citations
  Efficacy of Nilotinib in Patients With Moderately Advanced Parkinson Disease: A Randomized Clinical Trial.
  Tanya Simuni, Brian K. Fiske, Kalpana Merchant, Christopher S. Coffey, Elizabeth A. Klingner, Chelsea Caspell-Garcia, David-Erick Lafontant, Helen Matthews, Richard K....> ;JAMA Neurology. 2021 Mar 1
• 32 citations
  Safety and Tolerability of Cannabidiol in Parkinson Disease: An Open Label, Dose-Escalation Study.
  Maureen A. Leehey, Ying Liu, Felecia M. Hart, Christen Epstein, Mary N. Cook, Stefan Sillau, Jost Klawitter, Heike Newman, Cristina Sempio, Lisa Forman, Lauren Seeberg...> ;Cannabis and Cannabinoid Research. 2020 Dec 15
• 10 citations
  Safety and Tolerability of SRX246, a Vasopressin 1a Antagonist, in Irritable Huntington's Disease Patients-A Randomized Phase 2 Clinical Trial.
  Michael J Brownstein, Neal G. Simon, Jeffrey D. Long, Jon W. Yankey, Hilda T Maibach, Merit Cudkowicz, Christopher S. Coffey, Robin Conwit, Codrin Lungu, Karen E. Ande...> ;Journal of Clinical Medicine. 2020 Nov 16
• 42 citations
  Complementary Therapies in Parkinson Disease: a Review of Acupuncture, Tai Chi, Qi Gong, Yoga, and Cannabis
  Lisa M. Deuel, Lauren Seeberger> ;Neurotherapeutics. 2020 Oct 1
• 39 citations
  Novel clinical features of glycine receptor antibody syndrome: A series of 17 cases.
  Amanda L. Piquet, Murtaza Khan, Judith E. A. Warner, Matthew Wicklund, Jeffrey Bennett, Maureen A. Leehey, Lauren Seeberger, Teri Schreiner, M. Mateo Paz Soldan, Stace...> ;Neurology(R) Neuroimmunology & Neuroinflammation. 2019 Sep 1
• 6 citations
  Valbenazine for the treatment of tardive dyskinesia.
  Lauren Seeberger, Robert A. Hauser> ;Expert Opinion on Pharmacotherapy. 2017 Jul 12
• 85 citations
  A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
  Andrew McGarry, Michael P. McDermott, Karl Kieburtz, Elisabeth A. deBlieck, Flint Beal, Karen Marder, Christopher A. Ross, Ira Shoulson, Peter R. Gilbert, William Mall...> ;Neurology. 2017 Jan 10
• 37 citations
  Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials
  Kevin M. Biglan, Ira Shoulson, Karl Kieburtz, David Oakes, Elise Kayson, M. Aileen Shinaman, Hongwei Zhao, Megan Romer, Anne Young, Steven M. Hersch, J. B. Penney, Kar...> ;JAMA Neurology. 2016 Jan 1
• 12 citations
  Carbidopa levodopa enteral suspension.
  Lauren Seeberger, Robert A. Hauser> ;Expert Opinion on Pharmacotherapy. 2015 Nov 23
• 8 citations
  Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.
  Ronald E. Wilson, Lauren Seeberger, Dee E. Silver, Alida Griffith, Jill B. Conner, Phyllis M. Salzman> ;The Neurologist. 2011 Nov 1
• 14 citations
  Examination of the UPDRS Bradykinesia Subscale: Equivalence, Reliability and Validity
  Philip O Buck, Ronald E. Wilson, Lauren Seeberger, Jill B. Conner, Jane Castelli-Haley> ;Journal of Parkinson's Disease. 2011 Jan 1
• 22 citations
  Movement disorders associated with aripiprazole use: a case series.
  Deborah A. Hall, Pinky Agarwal, Alida Griffith, Vicki Segro, Lauren Seeberger> ;The International Journal of Neuroscience. 2009 Nov 16
• 23 citations
  Levodopa/carbidopa/entacapone in Parkinson's disease.
  Lauren Seeberger, Robert A. Hauser> ;Expert Review of Neurotherapeutics. 2009 Jul 1
• 13 citations
  Optimizing bioavailability in the treatment of Parkinson's disease.
  Lauren Seeberger, Robert A. Hauser> ;Neuropharmacology. 2007 Dec 1
• 29 citations
  Predictors of diagnosis in Huntington disease.
  Douglas R. Langbehn, Jane S. Paulsen, Phillipa Hedges, Elizabeth McCusker, Samantha Pearce, Ronald Trent, David A. Abwender, Peter Como, Irenita Gardiner, Charlyne Hic...> ;Neurology. 2007 May 15
• 15 citations
  MS vs. HD: can white matter and subcortical gray matter pathology be distinguished neuropsychologically?
  Jose M. Lafosse, John R. Corboy, Maureen A. Leehey, Lauren Seeberger, Christopher M. Filley> ;Journal of Clinical and Experimental Neuropsychology. 2007 Jan 30
• 25 citations
  Mutations in LRRK2 other than G2019S are rare in a north-American based sample of familial Parkinson's didease
  Nathan Pankratz, Michael W. Pauciulo, V. E. Elsaesser, Diane K. Marek, Cheyl A. Halter, Alice Rudolph, Clifford W. Shults, Tatiana Foroud, William C. Nichols, Cliff Sh...> ;Movement Disorders. 2006 Dec 1
• 86 citations
  Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia.
  Nathan Pankratz, Lisa Byder, Cheryl Halter, Alice Rudolph, Clifford W. Shults, P. Michael Conneally, Tatiana Foroud, William C. Nichols, Kelly E. Lyons, Karen Marder, ...> ;Movement Disorders. 2006 Jan 1
• 39 citations
  Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis
  Paul O'Connor, David Miller, Katherine Riester, Minhua Yang, Michael Panzara, Catherine M. Dalton, Katherine A. Miszkiel, Omar Khan, George Rice, William A. Sheremata,...> ;Multiple Sclerosis. 2005 Oct 1
• 158 citations
  Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.
  Daniel D. Truong, Drake D. Duane, Joseph Jankovic, Carlos Singer, Lauren Seeberger, Cynthia L. Comella, Mark F. Lew, Robert L. Rodnitzky, Fabio Danisi, James Sutton, P...> ;Movement Disorders. 2005 Jul 1
• 25 citations
  Long-term safety, efficacy, dosing, and development of resistance with botulinum toxin type B in cervical dystonia.
  Brian Berman, Lauren Seeberger, Rajeev Kumar> ;Movement Disorders. 2005 Feb 1
• 1310 citations
  By Carrot or by Stick: Cognitive Reinforcement Learning in Parkinsonism
  Michael J. Frank, Lauren Seeberger, Randall C. O'Reilly> ;Science. 2004 Dec 10
• Join now to see all

Journal Articles

• A Randomized, Double-blind, Placebo-Controlled Study of Latrepirdine in Patients With Mild to Moderate Huntington's Disease  
  Horizon Investigators of the Huntington Study Group and EHDN, JAMA Neurol, 1/1/2013
• Activity enhances dopaminergic long duration response in Parkinson's Disease  
  Kang UJ, Auinger P on behalf of the ELLDOPA Investigators, Neurology, 1/1/2012
• Characterization of a Large Group of Individuals with Huntington's disease and Their Relatives Enrolled in the COHORT Study  
  Dorsey ER, the Huntington Study Group Cohort Investigators, PLoS ONE, 1/1/2012
• Examination of the UPDRS Bradykinesia Subscale: Equivalence, Reliability, and Validity  
  Buck PO, Wilson RE, Seeberger LC, Conner JB, Castelli-Haley J, Journal of Parkinson's Disease, 1/1/2011
• Investigation of the Psychometric Properties of the Short Parkinson's Evaluation Scale/ Scales for Outcomes in Parkinson's Disease (SPES/SCOPA)  
  Wilson RE, Seeberger LC, Buck PO, Conner JB, Castelli-Haley J, Value in Health, 1/1/2011
• Suicidal Ideation in Huntington Disease: The Role of Comorbidity  
  Wetzel HH, Gehl CR, Dellefave-Castillo L, et al, and the Huntington Study Group, Psych Research, 1/1/2011
• Comorbidities of obsessive and compulsive symptoms in Huntington's disease  
  Anderson K, Gehl C, Marder, Beglinger LJ, Paulsen JS and the HSG Study Group, J Nerv Ment Dis, 1/1/2010
• Stalevo (levodopa/carbidopa/entacapone) in Parkinson's disease  
  Seeberger LC, Hauser RA, Expert Review of Neurotherapeutics, 1/1/2009
• Movement Disorders Associated with Aripiprazole Use: A Case Series  
  Hall DA, Agarwal P, Griffith A, Segro V, Seeberger LC, International Journal of Neuroscience, 1/1/2009
• Assessment of Dietary Intake Among Adults At Risk for Huntington Disease: Analysis of PHAROS Research Participants  
  Marder K, Hongwei Z, Tanner CM, et al and the Huntington Study Group PHAROS Investigators, Neurology, 1/1/2009
• Long term treatment with Botulinum toxin type A in Cervical Dystonia has low immunogenicity in Mouse Protection Assay  
  Brin MF, Comella CL, Jankovic J, et al. and the CD 017 BoNTA Study Group, Movement Disorders, 1/1/2008
• Randomized controlled trial of ethyl-EPA in Huntington Disease: The TREND HD Study  
  Dorsey ER, Beck CA, Adams M, et al and the Huntington Study Group TREND HD Investigators, Arch Neurol, 1/1/2008
• Study of Istradefylline in Patients with Parkinson's Disease on Levodopa with Motor Fluctiations  
  Hauser RA, Shulman LM, Trugman JM, et al and the Istradefylline 6002-US-13 Study Group, Movement Disorders, 1/1/2008
• MS vs HD: Can white matter and subcortical gray matter be distinguished neuropsychologically?  
  Lafosse JM, Corboy JR, Leehey MA, Seeberger LC, Filley CM, J Clinical and Experimental Neuropsychology, 1/1/2007
• Optimizing bioavailability in the treatment of Parkinson's disease  
  Seeberger LC, Hauser RA, Neuropharmacology, 1/1/2007
• Verbal episodic memory declines prior to diagnosis in Huntington's disease  
  Solomon AC, Stout JC, Johnson SA, Langbehn DR, et al., Predict-HD Investigators of the HSG, Neuropsychologia, 1/1/2007
• The mixed lineage kinase inhibitor CEPT-1347 fails to delay disability in early Parkinson's Disease  
  The Parkinson's Study Group PRECEPT investigators, Neurology, 1/1/2007
• Preparing for preventative clinical trials: the Predict-HD study  
  Paulsen JS, Hayden M, Stout JC, Langbehn DR, et al and the Predict-HD investigators of the HSG, Archives of Neurology, 1/1/2006
• Topiramate in essential tremor: a double-blind, placebo-controlled trial  
  Ondo WG, Jancovic J, Connor GS, et al; Topiramate Essential Tremor Study Investigators, Neurology, 1/1/2006
• Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia  
  Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC and the Parkinson Study Group-PROGENI Investigators, Mov Disord, 1/1/2006
• At risk for Huntington's disease: the PHAROS cohort enrolled  
  The Huntington Study Group Pharos Investigators, Archives of Neurology, 1/1/2006
• A randomized, controlled trial of Etilevodopa in Parkinson disease patients with motor fluctuations  
  Parkinson Study Group, Archives of Neurology, 1/1/2006
• Mutations in LRRK2 other than G2019S are rare in a North American-based sample of familial Parkinson disease  
  Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK et al, and the Parkinson Study Group-PROGENI Investigators, Movement Disorders, 1/1/2006
• Efficacy and Safety of Botulinum Type A Toxin (Dysport) in Cervical Dystonia: Results of the First US Randomized, Double-Blind, Placebo-Controlled Study  
  Truong D, Duane D, Jankovic J, Singer C, Seeberger LC, Comella C, Lew M, Rodinitsky R, Danisi F, Sutton J, Charles PD, Hauser R, Shecan G, Movement Disorders, 1/1/2005
• Long-term safety, efficacy, dosing and development of resistance with botulinum type B in cervical dystonia  
  Berman B, Seeberger LC, Kumar R, Movement Disorders, 1/1/2005
• Join now to see all

Books/Book Chapters

• Encyclopedia of Movement Disorders 
  Chapter: Huntington's Disease. 
  Page 39 - 49Seeberger LCEditors: Kompoliti K, Verhagen ML.Academic Press, Oxford2010
• Handbook of Essential Tremor and Other Tremor Disorders 
  Chapter: Cerebellar Tremor. 
  Page 227 - 243Hauser RA, Seeberger LCEditors: Lyons KE, Pahwa R.Taylor and Francis, Boca Raton, FL2005
• Medlink Neurology 
  Chapter: Huntington's Disease. 
  Agarwal P, Seeberger LCEditors: Gilman S, Goldstein GW, Waxman SG.Arbor Publishing, San Diego, CA2004
• Clinical Pain Management: Practical Applications and Procedures Volume 
  Chapter: Botulinum Toxin Injections. 
  Page 277 - 283Seeberger LC, O'Brien CFEditors: Breivik H, Eccleston C.Arnold, Ltd., London, England2002
• Clinical Pain Management: Chronic Pain Volume 
  Chapter: Management of painful Spasticity. 
  Page 459 - 466O'Brien CF, Seeberger LCEditors: Wilson P, Jensen T, Rice A.Arnold, Ltd., London, England2002
• Clinical Evaluation and Management of Spasticity: Current Clinical Neurology Series 
  Chapter: Botulinum Toxin Treatment in Spasticity. 
  Page 173 - 186Seeberger LC, O'Brien CFEditors: Gelber DA, Jeffrey D.Humana Press, NJ2001
• Medlink 
  Chapter: Huntington's Disease. 
  Seeberger LCEditors: Gilman S, Goldstein GW, Waxman SG.Arbor Publishing, San Diego, CA1999
• Caring for the Parkinson's Disease Patient: A Practical Guide 
  Chapter: Sexuality in Parkinson's Disease. 
  Page 122 - 130Seeberger LCEditors: Hutton JT and Dippel RL.Prometheus Books, New York, NY1999
• Neurobase 
  Chapter: Huntington's Disease. 
  Seeberger LCEditors: Gilman S, Goldstein GW, Waxman SG.Arbor Publishing, San Diego, CAEdition 1st,1998
• Handbook of Dystonia 
  Chapter: Phenol Injections in Dystonia. 
  Page 371 - 380Seeberger LCEditors: Stacy MA.
• Join now to see all

Abstracts/Posters

• Ropinirole has a lesser incidence compared to other dopamine agonists of causing compulsive behavior in Parkinson's disease patients.
  Agarwal P, Seeberger LC, Segro V, 10th International Congress of Movement Disorders, Kyoto, Japan, 1/28/2006
• Sudden onset of sleep attacks in a non parkinsonian patient on pramipexole for fibromyalgia.
  Agarwal P, Seeberger LC, Segro V, 10th International Congress of Movement Disorders, Kyoto, Japan, 1/28/2006
• Suicide in a patient with segmental dystonia and successful deep brain stimulation of the globus pallidus internus.
  Agarwal P, Seeberger LC, Segro V, 10th International Congress of Movement Disorders, Kyoto, Japan, 1/28/2006
• Double-blind, randomized study of BOTOX purified neurotoxin complex for treating focal spasticity poststroke.
  Botox Spasticity Study Group, Toxins 2002, Hannover, Germany, 1/1/2002
• Botulinum toxin type B for Limb Spasticity.
  O'Brien CF, Mancini F, Seeberger LC, International Conference Toxins, 1/1/2002
• Persistent Dyskinesia Associated With Serotonin Re-Uptake Inhibitors.
  Seeberger LC, O'Brien CF, Movement Disorders, Vienna, Austria, 1/1/1996
• Primary Postural Tremor in Parkinson's Disease.
  Seeberger LC, Sage JI, Third International Congress of Movement Disorders, Orlando, FL, 1/1/1994
• Idiopathic Cardiomyopathy-a Retrospective Study of Heart Sizes at Autopsy.
  Seeberger LC, Kent S, National Student Research Day and 1986 National FASEB Convention, 1/1/1986
• Join now to see all

Lectures

• "Surgical Interventions in Parkinson's Disease." 
  Boise, ID - 1/16/2014
• "Brass Tacks of Running GCP Compliant Trials." 
  Minneapolis, MN - 1/7/2014
• "Clinical Trials in HD." 
  University of Utah, Salt Lake City, UT - 1/18/2013
• "DBS Treatment for Parkinson's Disease." 
  Boise, ID - 1/19/2012
• "Parkinsonism: Clinical Features and Diagnosis." 
  Sun Valley, ID - 1/1/2011
• "NeuroRehabilition National Preceptor Program" 
  1/1/2010
• "WE MOVE Primidone for Subcortical Myoclonus." 
  1/1/2010
• "Parkinson's Disease: Diagnosis and Management." 
  1/1/2010
• "Rural Medicine, Outreach and Research." 
  1/1/2010
• "Treatment of Non-Motor Features of Parkinson's Disease." 
  University of South Florida, Orlando, FL - 1/24/2009
• "Video Overview of Movement Disorders" 
  Sun Valley, ID - 1/1/2009
• "WE MOVE Drug Induced Movement Disorders" 
  1/30/2008
• "Diagnosis and Management of Movement Disorders" 
  Sun Valley, ID - 1/16/2008
• "Understanding Parkinson's Disease." 
  Sun Valley, ID - 1/16/2008
• Grand Rounds: "Pearls in Treating Parkinson's Disease." 
  ACMEC St. Luke's Regional Medical Center, Boise, ID - 1/10/2008
• "Recognition and Overview of Movement Disorders." 
  St. Luke's Medical Center, Boise, ID - 1/26/2007
• "Non-motor Features of PD with an Intensive Review of Anatomy and Physiology of the Sense of Smell." 
  Portland, OR - 1/16/2007
• "Recognition and Overveiw of Movement Disorders." 
  St. Alphonsus Medical Center, Boise, ID - 1/15/2007
• "Botulinum Toxin Treatment for Neurological Disorders." 
  Tampa, FL - 1/15/2007
• "Non-Motor Manifestations of PD and their Treatment." 
  Savannah, GA - 1/11/2007
• Faculty, "Moving Forward: 2nd Edition A Practical Guide to living with Parkinson's disease." 
  1/1/2007
• "Parkinson's Disease Scientific Advisory Board Meeting" 
  Kansas City, MO - 1/21/2006
• "Basics of Parkinson's disease treatment." 
  Sun Valley, ID - 1/13/2006
• "Overview of Biomarkers in Dystonia." 
  Denver, CO - 1/10/2005
• "Parkinson Disease Diagnosis and Treatment." 
  Vail, CO - 1/6/2005
• Join now to see all

Other

• "WeMove Post-stroke Spasticity Management Initiative" 
  Lauren Seeberger, MD
  1/1/2007
• "Huntington disease." 
  Agarwal P, Seeberger LC, MedLink Neurology
  1/1/2006
• "The role of chemodenervation in Spasticity management." 
  Lauren Seeberger, MD, WeMove Web CME Module
  http://www.mdvu.org/classrooms/cme/spasticity_chemd
  1/1/2005
• "Spasticity: Pathophysiology, Assessment and Management." 
  Lauren Seeberger, MD, WeMove Teaching Slide Set Development
  1/1/2001
• "Huntington's Disease. VanderArk G, editor" 
  Seeberger LC, Colorado Neurological Institute Review, Winter Edition
  Englewood, CO - 1/1/1999
• "Restless Legs Syndrome. VanderArk G, ed." 
  Seeberger LC, Colorado Neurological Institute Review, Spring Edition
  Englewood, CO - 1/1/1999
• Reliability of Measurements of Patient Health Status: A Comparison of Physician, Patient and Caregiver Ratings. 
  McRae C, O'Brien CF, Seeberger LC, and Vo A, Fifth International Congress of Parkinson's Disease and Movement Disorders
  New York City, NY - 1/1/1998
• A New Treatment for Tremor in Multiple Sclerosis. 
  Seeberger LC, Murray R, MS Connection
  1/1/1997
• Join now to see all